Search company, investor...

Predict your next investment

Private Equity
ftlcapital.com

Investments

5

Portfolio Exits

3

About FTL Capital

FTL Capital is striving to move from success to significance to become a preeminent boutique private equity firm by inspiring the growth of people, portfolio companies and returns through active proven leadership and engagement. Based in St. Louis, the firm was formed in 2001 to invest capital of its Managing Principals, Thomas J. Hillman and Paul D. Melnuk. FTL focuses on the "hard stuff" – the culture and values – to help portfolio companies grow profitably over the long term. Underlying that driving focus are proven professional skill sets tested and honed through decades of experience deeply rooted in the "soft stuff" – leading, directing, operating, acquiring, funding, building, restructuring, and monetizing businesses large and small.

Headquarters Location

120 S. Central Avenue Suite 1000

St. Louis, Missouri, 63105,

United States

314-392-5257

Want to inform investors similar to FTL Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest FTL Capital News

In the money: 6 St. Louis startups that have raised money so far in March

Mar 16, 2015

At least half a dozen startup companies that call St. Louis home raised money from investors in the first half of March, according to Business Journal reporting and federal filings. Those companies include: — RoverTown, the St. Louis startup that offers coupons and deals to college students via its mobile app, raised $875,000 from a group of investors that includes former Anheuser-Busch President Dave Peacock , Tom Hillman of FTL Capital, and David Karandish and Chris Sims of Answers. — Veniti, a medical device startup based in St. Louis, raised more than $17 million in a Series C financing round led by previous investors Baird Capital, Tekla Healthcare and Tekla Life Science Investors. — SynerZ Medical Inc., a medical device startup in St. Louis, raised $650,000 of a planned $1.2 million financing round from a group of local investors. — LemnaTec, a company that sells hardware and software for taking digital images of plants and processing them to produce phenotypic data, raised $5.4 million to support the company's global expansion plans, including St. Louis. — Apse LLC, the St. Louis startup that has developed technology to mass produce RNA (ribonucleic acid), raised $350,000 in seed money from a group of investors that includes BioGenerator. — EternoGen Aesthetics, a St. Louis-based startup developing an alternative to Botox, has raised more than $700,000 from a group of investors that includes the Missouri Technology Corp. TechFlash: St. Louis' best tech news in your inbox, every weekday. Subscribe for free here . Tech, Venture Capital, Startups, Real Estate Related links:

FTL Capital Investments

5 Investments

FTL Capital has made 5 investments. Their latest investment was in Pulse Therapeutics as part of their Series B on January 1, 2016.

CBI Logo

FTL Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/27/2016

Series B

Pulse Therapeutics

$10M

No

1

2/6/2014

Series A - III

Subscribe to see more

$99M

Subscribe to see more

10

8/27/2013

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/13/2012

Series A - II

Subscribe to see more

$99M

Subscribe to see more

0

4/21/2011

Series A

Subscribe to see more

$99M

Subscribe to see more

0

Date

1/27/2016

2/6/2014

8/27/2013

1/13/2012

4/21/2011

Round

Series B

Series A - III

Series A

Series A - II

Series A

Company

Pulse Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$10M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

0

0

FTL Capital Portfolio Exits

3 Portfolio Exits

FTL Capital has 3 portfolio exits. Their latest portfolio exit was Pulse Therapeutics on January 08, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/8/2019

Merger

$99M

1

4/18/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

2/5/2016

Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/8/2019

4/18/2017

2/5/2016

Exit

Merger

Acquired

Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

10

10

FTL Capital Acquisitions

1 Acquisition

FTL Capital acquired 1 company. Their latest acquisition was Teachers-Teachers on December 01, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/1/2014

$99M

Acq - Fin

1

Date

12/1/2014

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acq - Fin

Sources

1

FTL Capital Team

2 Team Members

FTL Capital has 2 team members, including current Managing Partner, Paul Melnuk.

Name

Work History

Title

Status

Paul Melnuk

Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Paul Melnuk

Subscribe to see more

Work History

Title

Managing Partner

Subscribe to see more

Status

Current

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.